Repair Biotechnologies develops a Cholesterol Degrading Platform that targets and reduces atherosclerotic plaque in arteries, a primary contributor to cardiovascular diseases such as heart attacks and strokes. This platform offers a tailored therapeutic approach to address conditions arising from excess cholesterol accumulation in various tissues.
Funding
$17.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELJMFounders
Product
Problem
Cardiovascular diseases, including heart attacks and strokes, remain a leading cause of mortality worldwide, with atherosclerosis, the buildup of cholesterol-based plaque in arteries, being a primary contributor. Current treatments often fail to adequately address the existing plaque burden, leaving millions at risk. Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, leads to extremely accelerated atherosclerosis and significantly reduced life expectancy if untreated.
Solution
Repair Biotechnologies is developing a Cholesterol Degrading Platform (CDP) designed to reduce atherosclerotic plaque and address conditions arising from localized cholesterol accumulation. The CDP therapy aims to shrink existing plaque burden, which is strongly correlated with reduced cardiovascular events. The platform is designed to be modular, allowing for tailoring to various indications and delivery mechanisms, including gene therapies. Initial clinical efforts are focused on homozygous familial hypercholesterolemia (HoFH), an orphan indication characterized by severely elevated LDL-C levels and early-onset atherosclerosis.
Target Audience
The primary target audience includes individuals with atherosclerosis and related cardiovascular diseases, particularly those with homozygous familial hypercholesterolemia (HoFH) and metabolic-dysfunction associated steatohepatitis (MASH).
Features
- CDP therapy designed to reduce atherosclerotic plaque burden in arteries.
- Modular platform adaptable to various indications where localized cholesterol excess drives pathology.
- Potential application in treating metabolic-dysfunction associated steatohepatitis (MASH) by reversing liver fibrosis in animal studies.
- Gene therapy approach targeting conditions associated with aging, obesity, and inherited mutations affecting cholesterol metabolism.
- Demonstrated rapid and robust reduction of plaque burden in mouse models.
- Currently pursuing clinical pathway through homozygous familial hypercholesterolemia (HoFH).
- Collaboration with Genevant Sciences to develop mRNA-LNP therapy.